Shares of Arcellx, Inc. (NASDAQ:ACLX – Get Free Report) have received a consensus recommendation of “Buy” from the fifteen ...

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

Generation Bio (GBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from ...

On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...

Gil Blum, an analyst from Needham, maintained the Buy rating on Taysha Gene Therapies (TSHA – Research Report). The associated price target ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports.

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.51 billion, has been making waves in the biotechnology sector with its innovative approach to cell therapy for multiple ...

Cell therapy developer Arcellx contends its lead program could be a safer alternative to currently available CAR T-treatments for multiple myeloma, noting that its previously reported preliminary ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.51 billion, has been making waves in the biotechnology sector with its innovative approach to cell therapy for multiple ...

In the latest quarter, 14 analysts provided ratings for Arcellx (NASDAQ:ACLX), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.57 billion, has been making waves in the cell therapy space with its innovative approach to treating multiple myeloma and ...